1. |
Inhibition of cyclo-oxygenase and lipoxygenase reviewed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1317,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1317,
2001,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Cellular immunotherapy for cancer treatment reviewed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1317,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1317,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1317,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
Sumatriptan of economic benefit in migraine |
|
Inpharma Weekly,
Volume &NA;,
Issue 1317,
2001,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1317,
2001,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
ZD 0473: overcoming resistance to platinum-based chemotherapy? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1317,
2001,
Page 9-10
Sushma Soni,
Preview
|
|
摘要:
ZD 0473 shows activity in various treatment-refractory solid tumours both as monotherapy and in combination with other antineoplastics, according to data from phase I and II studies presented at ECCO 11 - the European Cancer Conference [Lisbon, Portugal; October 2001]. ZD 0473 is a new generation platinum compound which was designed with the intention of overcoming resistance to existing platinum-based antineoplastics. While it is not yet clear whether this objective has been achieved, clinical studies suggest ZD 0473 may be better tolerated than older platinum compounds, with no evidence of neurotoxicity or nephrotoxicity associated with the newer agent to date.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1317,
2001,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
Massive benefits for patients at risk of CHD in largest lipid-lowering trial |
|
Inpharma Weekly,
Volume &NA;,
Issue 1317,
2001,
Page 13-14
Larry Prescott,
Preview
|
|
摘要:
Cholesterol-lowering with HMG CoA reductase inhibitors [statins] reduces the risk of myocardial infarction (MI) and stroke by at least one-third, and reduces the need for arterial surgery, angioplasty and amputations, according to data from the Heart Protection Study (HPS), the world's largest lipid-lowering trial. Moreover, the benefits were seen irrespective of age, gender or history of MI, diabetes mellitus, hypertension or vascular disease, and even if cholesterol levels were not high enough to require statin therapy under current guidelines. Results from the HPS, conducted by the UK Medical Research Council and British Heart Foundation, were presented at the Scientific Sessions of the American Heart Association [Anaheim, US; November, 2001].*
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|